SentiSense
Ctrl+K
Quick tip: Press
to search stocks
B
BMY
Bristol Myers Squibb Company
$60.29
-0.45 (-0.74%)
Summary
Stories
News
Metrics
Fundamentals
Current Market Valuation
Current Price
$60.29
Live market price
P/E (TTM)
17.48
EPS: $3.45
P/S (TTM)
2.55
Price to Sales
TTM Quarters
4
Quarters included in TTM
Updated: 3/8/2026, 10:24:55 PM
Historical Trends
Range:
Revenue Over Time
Net Income Over Time
Short Interest (% of Float) Over Time
Short Interest
31.7M
% of Float
1.6%
Days to Cover
2.2
Avg Daily Vol
14.6M
Historical income statement data up to 5 years
Historical SEC Filings
Report Period
Debt/Equity
2.42
Leverage ratio
ROE (TTM)
38.12%
Return on equity
Income Statement
Revenue
$48.19B
Cost of Revenue
$13.94B
Gross Profit
$34.26B
Operating Income
$9.33B
Net Income
$7.05B
EPS (Quarter)
$3.46
EPS (TTM)
--
Balance Sheet
Total Assets
$90.04B
Total Liabilities
$71.53B
Shareholders' Equity
$18.51B
Current Assets
$29.39B
Current Liabilities
$23.42B
Cash & Equivalents
--
Long-Term Debt
$44.83B
Cash Flow
Operating Cash Flow
$14.16B
Investing Cash Flow
$-4.13B
Financing Cash Flow
$-10.35B
Free Cash Flow
$10.02B
Profitability Margins
Gross Margin
71.08%
Operating Margin
19.36%
Net Profit Margin
14.64%
ROA (TTM)
7.84%
ROE (TTM)
38.12%
Data source: Polygon.io
Last updated: 3/8/2026, 10:24:55 PM
Company Profile
Symbol
BMY
Market Cap
$122.78B
IPO Date
Jun 23, 1952
CEO
Chris Boerner
Employees
32,500
Sector
--
Industry
PHARMACEUTICAL PREPARATIONS
Country
United States
Exchange
--
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Read MoreSimilar Stocks
ABBV
AbbVie Inc.
$230.11
-0.96%
MRK
Merck & Co., Inc.
$115.79
-0.24%